Anhui provincial hospital
Hefei, China
Location status: Recruiting
NCT Number: NCT06602843
The goal of this study was to explore the efficacy and safety of neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy in patients with locally advanced esophageal squamous cell carcinoma
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Not applicable
Hefei, China
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
Time frame: immediately after the intervention/procedure/surgery
Pathologic Complete Response
Time frame: immediately after the intervention/procedure/surgery
R0 resection rate
Time frame: immediately after the intervention/procedure/surgery
1#3-year disease free survival
Anhui Provincial Hospital
Other Gov
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05028725
Carcinoma, Carcinoma, Squamous Cell
Dar es Salaam, Mloganzila, Tanzania
View Trial DetailsNCT07090499
Adenocarcinoma, Adenocarcinoma Of Esophagus
Duarte, California, United States
View Trial DetailsNCT07554521
Advanced Gastroesophageal Adenocarcinoma, Advanced Unresectable Gastric Adenocarcinoma
Los Angeles, California, United States
View Trial DetailsNCT05208762
Adenocarcinoma, Breast Diseases
Birmingham, Alabama, United States
View Trial Details